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Background/Purpose: The objective of this study was to characterize the 10-year trend in prescriptions of
z-hypnotics among the elderly in Taiwan, focusing on duration and dosages of the z-hypnotics pre-
scribed. Data from the 2001e2010 Taiwan National Health Insurance Research Database (NHIRD) were
used for this study.
Methods: Incident users of hypnotics[z-hypnotics and benzodiazepine (BZD)], aged 65 years, for each
ﬁscal year from 2001 to 2010 were identiﬁed from the Longitudinal Health Insurance Database 2000 and
2005 of NHIRD. The annual prevalence of z-hypnotic and BZD prescriptions was reported for each ﬁscal
year during 2001e2010. Demographics of patients who received z-hypnotics and characteristics of their
providers were described. Several measures, including prescription duration, daily pills, and daily dosage,
were used to quantify the use of z-hypnotics in the elderly.
Results: During 2001e2010, the annual use of z-hypnotics per elderly patient was doubled: from 3.1
prescriptions in 2001 to 5.8 prescriptions of z-hypnotics annually in 2010. A similar pattern was observed
in the annual use of BZD per elderly patient (3.2 prescriptions in 2001 to 5.5 prescriptions of BZD in
2010). The frequency of z-hypnotic prescriptions from medical centers decreased from 33.6% in the ﬁscal
year 2001 to 19.7% in the ﬁscal year 2010. In recent years, most z-hypnotics were prescribed by clinics
(38.6% in 2010) and by physicians not specializing in psychiatry. The frequency of zolpidem prescriptions
was 66.6% in 2001, which increased to 86.7% in 2010. The most frequent prescription duration of
z-hypnotics was 8e30 days, followed by 4e7 days and 3 days. Over 70e80% of the z-hypnotic pre-
scriptions contained more than 1 weeks’ supply of z-hypnotics.
Conclusion: Our empirical ﬁndings revealed a signiﬁcant nationwide outpatient consumption of z-hyp-
notics in Taiwan. To our knowledge, our study was the ﬁrst one to conduct an in-depth examination of
patients’ and providers’ characteristics associated with z-hypnotics use among the elderly.
Copyright  2013, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC.  Open access under CC BY-NC-ND license.1. Introduction
Use of hypnotics among the elderly continues to increase as the
prevalence of insomnia increases with age. A considerable increase
in the use of new nonbenzodiazepine (non-BZD) hypnotics, such as
zolpidem, zopiclone, and zaleplon (the so-called “z-hypnotics”),
has also been noticed.1 The increased use of z-hypnotics may be due
to the perception that z-hypnotics have a better safety proﬁle than
the older BZD hypnotics.2,3 However, signiﬁcant concerns regardingtion 1, Taipei 10051, Taiwan.
linical Gerontology & Geriatrics. Pthe use of z-hypnotics and associated potential adverse events,
including accidental falls,4 fracture,5,6 and cognitive decline,7
remain. Age-related pharmacokinetics and pharmacodynamics
exposes the elderly to a particular risk of adverse events associated
with the use of z-hypnotics. Therefore, an appropriate use of
z-hypnotics in the elderly is of signiﬁcant concern. According to
current guidelines, the elderly should only use z-hypnotics at low
doses and for a short period of time (less than 1month)8,9 However,
some studies have reported an increasing prevalence of long-term
use of z-hypnotics in the elderly population, which may result in
serious adverse events.7,10 While the safety of z-hypnotics is
of signiﬁcant public concern, available information on the use ofublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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old-age groups) is very limited. Using the 2001e2010 Taiwan
National Health Insurance research database (NHIRD), this study
aimed to characterize the 10-year trend in prescription of z-hyp-
notics among the elderly in Taiwan, focusing on the patient char-
acteristics (age and gender distribution), provider characteristics,




Data of this population-based cross-sectional study were
obtained from the ambulatory claims database of the NHIRD in
Taiwan. The NHIRD is a nationwide database comprising anony-
mous eligibility and enrollment information, as well as claims for
visits, procedures, and prescription medications of more than 99%
of the entire population (23 million) in Taiwan. Individual patients
have been recorded as entering the NHIRD when they are covered
by Taiwan’s mandatory National Health Insurance program, which
was established in 1996, and leaving it at their death. Two subsets
of the NHIRD, the Longitudinal Health Insurance Database (LHID)
2000 and LHID2005, contain claims data of 1 million beneﬁciaries
randomly selected from the Registry of Beneﬁciaries of the NHIRD
in 2000 and 2005, respectively. The LHID2000 and LHID2005 thus
include approximately 10% of the total population in Taiwan. The
details of the NHIRD are described in the NHIRD website11 and in
our previous publication.12
2.2. Study cohort and prescriptions of z-hypnotics
Incident users of hypnotics (z-hypnotics and BZD), aged 65
years, for each ﬁscal year from 2001 to 2010 were identiﬁed from
the LHID2000 and LHID2005. We deﬁned incident users of hyp-
notics as those who received their ﬁrst outpatient prescriptions of
z-hypnotics (zolpidem, zopiclone, or zaleplon) or BZD during our
study period. A 2-year washout period was applied to ensure their
incident use. All outpatient z-hypnotic/BZD prescription records of
these incident users were further obtained from the LHID2000 and
LHID2005. For each z-hypnotic/BZD prescribed, the prescription
records of the LHID include information on starting date (date on
which the prescription was dispensed), dosages, quantities, and
prescription duration. Patient demographics (age and gender) and
provider information (prescribing physicians andmedical facilities)
are also included in the prescription records.
2.3. Statistical analyses
Annual prevalence of z-hypnotic/BZD prescriptions were
reported for each ﬁscal year from 2001 to 2010. Demographics of
patients who were prescribed z-hypnotics were described. Three
predeﬁned age groupsdthe young-old age group (65e74 years
old), middle-old age group (75e84 years old), and old-old age
group (85 years old and older)dwere used in our analyses. Details
on the use of z-hypnotics, including substance use and provider
characteristics, were further examined. Hospitals were charac-
terized by accreditation levels: medical center, regional hospital,
district hospital, and clinic. Prescribing physicians were grouped
according to their specialties (e.g., psychiatry). Several measures,
including prescription duration, daily pills, and daily dosage, were
used to quantify the use of z-hypnotics in the elderly. All analyses
were performed by SAS software (version 9.2; SAS Institute Inc.,
Cary, NC, USA).3. Results
The number of patients aged 65 years and older receiving pre-
scriptions for z-hypnotics increased nearly three-fold during our
study period, from 5877 in the ﬁscal year 2001 to 17,591 in the ﬁscal
year 2010. The increase in patient numbers resulted in a signiﬁcant
increase in the numbers of z-hypnotic prescriptions. Over 100,000
of z-hypnotic prescriptions were prescribed to the elderly in 2010.
On average, each patient received 3.1 and 5.8 prescriptions of z-
hypnotics annually in 2001 and 2010, respectively. Women were
prescribed more z-hypnotics than men. The gender distribution of
z-hypnotic users remained stable over time. Approximately 60% of
z-hypnotic prescriptions were prescribed to the young-old age
group, followed by 30% to the middle-old age group, and 5% to the
old-old age group in 2001. However, the distribution of age groups
among z-hypnotic users changed overtime, with an increased
proportion of old-old age group receiving z-hypnotics. A similar
pattern was observed in the annual use of BZD per elderly patient
(an increase from 3.2 in 2001 to 5.5 prescriptions of BZD annually in
2010). The number of incident BZD users was doubled during the
10-year period. The proportion of old-old age group receiving BZD
was also increased (Table 1).
In early years, most patients received their prescriptions for
z-hypnotics from medical centers. However, in recent years fewer
patients received their z-hypnotic prescriptions from medical
centers. The frequency of z-hypnotic prescriptions from medical
centers decreased from 33.6% in the ﬁscal year 2001 to 19.7% in the
ﬁscal year 2010. In recent years, most z-hypnotic prescriptions were
received from clinics (38.6% in 2010). Physicians specializing in
internal medicine prescribed approximately 30% of z-hypnotic
prescriptions during our study period. Less than 15% of z-hypnotic
prescriptions were prescribed by physicians specializing in psy-
chiatry (Table 2).
In the past decade, the dominant z-hypnotic was zolpidem. In
addition, an increased trend in the frequency of prescription of
zolpidemwas found. The frequency of prescription of zolpidemwas
66.6% in 2001, which increased to 86.7% in 2010. The most frequent
prescription durations of the z-hypnotics were 8e30 days, followed
by 4e7 days and 3 days. Over 70e80% of the z-hypnotic pre-
scriptions contained more than 1 week of z-hypnotics supply. Most
of the elderly patients were prescribed less than one pill of hyp-
notics daily, that is, approximately 78% and 15% of the elderly
received 0.5e1 and 0.5 pills, respectively, of hypnotics per day. As
a result, in over 95% of cases, the dosage of z-hypnotics prescribed
was within the maximum daily dosage (Table 3).4. Discussion
In this population-based cross-sectional study on the use of
z-hypnotics in the elderly, signiﬁcant increases in numbers of
patients and prescriptions were observed in the past 10 years
(2001e2010) in Taiwan. The most striking change was a three-fold
increase in the annual numbers of patients and a ﬁve-fold increase
in the annual numbers of z-hypnotic prescriptions. In 2010, 17,000
patients aged 65 years and older received approximately 100,000
prescriptions of z-hypnotics. The annual use of z-hypnotics per
patient also doubled during the same period, from 3.1 in 2001 to 5.8
prescriptions of z-hypnotics annually in 2010.
For comparison, we also reviewed the prescription patterns of
BZD in the elderly population and found similar results. The
increasing use of both z-hypnotics and BZD in the elderly pop-
ulation suggests that a potential replacement effect of z-hypnotics
over BZD may not exist. These changes have important clinical and
public health implications, as the increasing use of z-hypnotics/BZD
Table 1
Patient demographics and numbers of z-hypnotics and benzodiazepine prescriptions among the elderly, 2001e2010.
Years 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Z-hypnotics
Patient number 5877 9193 12,026 14,923 16,971 17,584 9156 18,179 18,371 17,591
Total prescriptions 18,505 38,427 54,619 74,669 90,141 96,367 49,260 105,659 104,708 101,809
Prescription/patient 3.1 4.2 4.5 5.0 5.3 5.5 5.4 5.8 5.7 5.8
Gender
Male, n (%) 8754 (47.3) 17,779 (46.3) 25,467 (46.6) 34,071 (45.6) 40,669 (45.1) 42,624 (44.2) 21,297 (43.2) 45,737 (43.3) 45,180 (43.1) 43,783 (43.0)
Female, n (%) 9751 (52.7) 20,648 (53.7) 29,152 (53.4) 40,598 (54.4) 49,472 (54.9) 53,743 (55.8) 27,963 (56.8) 59,922 (56.7) 59,528 (56.9) 58,026 (57.0)
Age (y)
65e74, n (%) 11,348 (61.3) 22,884 (59.5) 30,746 (56.3) 40,782 (54.6) 48,644 (54.0) 50,397 (52.3) 25,496 (51.8) 54,563 (51.6) 54,824 (52.4) 53,330 (52.4)
75e84, n (%) 6133 (33.2) 13,333 (34.7) 20,476 (37.5) 28,958 (38.8) 35,107 (38.9) 38,207 (39.6) 19,651 (39.9) 41,813 (39.6) 40,537 (38.7) 38,650 (38.0)
85, n (%) 1024 (5.5) 2210 (5.8) 3397 (6.2) 4929 (6.6) 6390 (7.1) 7763 (8.1) 4113 (8.3) 9283 (8.8) 9347 (8.9) 9829 (9.6)
Benzodiazepine
Patient number 10,576 12,331 13,287 15,079 15,772 16,904 8921 18,378 19,557 20,479
Total prescriptions 33,325 48,699 58,910 73,817 80,501 88,198 45,766 100,377 108,800 112,642
Prescription/patient 3.2 3.9 4.4 4.9 5.1 5.2 5.1 5.5 5.6 5.5
Gender
Male, n (%) 18,198 (54.6) 26,442 (54.3) 32,181 (54.6) 39,804 (53.9) 43,375 (53.9) 46,529 (52.8) 23,497 (51.3) 52,363 (52.2) 56,116 (51.6) 57,774 (51.3)
Female, n (%) 15,127 (45.4) 22,257 (45.7) 26,729 (45.4) 34,013 (46.1) 37,126 (46.1) 41,669 (47.2) 22,269 (48.7) 48,014 (47.8) 52,684 (48.4) 54,868 (48.7)
Age (y)
65e74, n (%) 22,595 (67.8) 31,600 (64.9) 36,925 (62.7) 45,025 (61.0) 48,171 (59.8) 51,906 (58.9) 26,794 (58.6) 58,153 (57.9) 62,305 (57.3) 64,477 (57.2)
75e84, n (%) 9283 (27.9) 14,853 (30.5) 18,965 (32.2) 24,478 (33.2) 27,668 (34.4) 30,276 (34.3) 15,304 (33.4) 34,938 (34.8) 38,093 (35.0) 38,923 (34.6)
85, n (%) 1447 (4.3) 2246 (4.6) 3020 (5.1) 4314 (5.8) 4662 (5.8) 6016 (6.8) 3668 (8.0) 7286 (7.3) 8402 (7.7) 9242 (8.2)
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population.
Although previous studies suggested that the use of z-hypnotics
increased with age,1,13 very few studies focused on the use of
z-hypnotics in different old-age groups. Noticeably, the proportion
of old-old age patients (those aged 85 years and older) receiving
z-hypnotics doubled from 5% to 10% of total patients during our
observed years. Our ﬁndings were consistent with the ﬁndings of
Johnell and Fastbom’s14 study that, in Sweden, 25% of those aged 75
years and older used one or more BZD/z-hypnotics per day.
Although the increasing consumption of z-hypnotics in this age
group is not surprising as the population is aging, it has raised more
concerns. First, evidence regarding the effectiveness and safety of
z-hypnotics in the very old population is lacking. Second, age was
reported in several studies15,16 as a signiﬁcant risk factor for falls
and fractures, especially z-hypnotic-related falls and fractures, in
the elderly population. For example, using data from the Korean
Health Insurance Review and Assessment database, Kang et al15
found that zolpidem exposure was associated with an increased
risk of facture in the elderly population, with the highest risk being
among those aged over 85 years [odds ratio (OR): 4.48;95% con-
ﬁdence interval (CI): 2.00e10.04]. Nevertheless, as BZD may also
carry the risk of drug abuse, dependence, tolerance, falls, and
fractures,1,17 the key to avoiding adverse events related to hypnotics
in the elderly relies mainly on the appropriate use of these drugs.
In our study, older women accounted for a larger proportion of
z-hypnotic users than men. This is consistent with the ﬁndings
reported by Bourgeois et al13 that BZD/z-hypnotic use was more
frequent in females (OR: 1.32, 95% CI: 1.03e1.68). Neutel and his
colleagues9 also reported that females accounted for 70% of elderly
people (aged 70e89 years) who ﬁlled at least two hypnotic pre-
scriptions in Norway. This could be due to a higher utilization of
health services by older women than older men, as reported in
previous studies.18 However, more research will be warranted in
addressing special medical demands in older women.
Provider variations observed in our study need special consid-
eration. During our study period, more and more elderly patients
received their z-hypnotics from clinics and from physicians not
specializing in psychiatry. Under a universal health insurance sys-
tem, the elderly in Taiwan could easily access health-care services,
especially primary clinics and general physicians, which wereavailable within walking distance. However, because of age-related
physiological changes, multiple comorbidities, and polypharmacy,
prescribing to the elderly could be very complicated. According to
the mostly cited Beer criteria,19,20 which evaluated the quality of
prescribing to the elderly, the prevalence of potentially inappro-
priate prescribing could reach 40% in some settings.21,22 Fur-
thermore, some studies have suggested that many primary doctors
had multiple barriers to appropriate prescribing in the elderly.23,24
Strategies initiated by professional organizations and health policy
makers will thus be needed to promote quality in prescribing to the
elderly.
Zolpidemwas the z-hypnotic prescribed most frequently during
our study period, which accounted for 85% of the total z-hypnotic
prescriptions. This is consistent with the ﬁndings from one pre-
vious study assessing patterns of sleep-related medications pre-
scribed to elderly outpatients with insomnia in Taiwan25 and
another study using dispensing data from a large sample of com-
munity pharmacies across Germany.26 However, little is known
about differences in terms of clinical effectiveness and safety pro-
ﬁles between zolpidem and other z-hypnotics. Because of its wide
use, many case reports suggesting potential associations between
zolpidem and its abuse or dependence have been released.26,27 This
does not imply that zolpidem may be the most hazardous z-hyp-
notic since similar cases were also identiﬁed in zopiclone users.28
A striking ﬁnding was that the use of z-hypnotics among the
elderly could be chronic, which is considered to be inappropriate. In
our study, the most frequent prescription duration of the z-hyp-
notics was 8e30 days. If we multiply 30 days of z-hypnotics sup-
plied by the annual prescriptions of z-hypnotics per patient (5.8
prescriptions in 2010), we will get approximately 180 days of
z-hypnotics supplied to our elderly patients. This indicates a high
possibility of long-term z-hypnotic use in the elderly and poses
signiﬁcant concerns regarding dependence on these agents and
subsequent adverse events. A similar phenomenon has been
reported by Siriwarden et al,29 who observed that more than 80% of
patients who received z-hypnotics took these agents for over 1 year.
Further research or policy interventions are therefore necessary to
explore potential abuse of and dependence on z-hypnotics in the
elderly population.
Some potential limitations should be taken into account while
interpreting the results of the present study. First, because our data
Table 3
Prescription substance, duration, daily use, and dosage of z-hypnotics prescribed for the elderly, 2001e2010.
Year 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Total prescriptions 18,505 38,427 54,619 74,669 90,141 96,367 49,260 105,659 104,708 101,809
Substance
Zolpidem, n (%) 12,325 (66.6) 28,989 (75.4) 44,530 (81.5) 63,067 (84.5) 77,919 (86.4) 84,135 (87.3) 42,819 (86.9) 92,125 (87.2) 91,030 (86.9) 88,244 (86.7)
Zopiclone, n (%) 6180 (33.4) 9438 (24.6) 10,089 (18.5) 11,602 (15.5) 12,222 (13.6) 12,232 (12.7) 6441 (13.1) 13,534 (12.8) 13,130 (12.6) 12,551 (12.3)
Zaleplon, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 548 (0.5) 1014 (1.0)
Durations (d)
<3, n (%) 1340 (7.2) 2609 (6.8) 3890 (7.1) 5636 (7.6) 6583 (7.3) 6893 (7.2) 3020 (6.1) 6515 (6.2) 6743 (6.4) 7216 (7.1)
4e7, n (%) 3734 (20.2) 6234 (16.2) 7980 (14.6) 9541 (12.8) 10,399 (11.5) 9585 (9.9) 3830 (7.8) 7452 (7.0) 7234 (6.9) 6774 (6.6)
8e30, n (%) 13,397 (72.4) 29,474 (76.7) 41,655 (76.3) 59,313 (79.4) 72,899 (80.9) 79,574 (82.6) 42,287 (85.8) 91,365 (86.5) 90,425 (86.4) 87,511 (86.0)
>30, n (%) 34 (0.2) 110 (0.3) 1094 (2.0) 179 (0.2) 270 (0.3) 315 (0.3) 123 (0.3) 327 (0.3) 306 (0.3) 308 (0.3)
Daily use (pills)
<0.5, n (%) 3456 (18.7) 6763 (17.6) 8337 (15.3) 10,830 (14.5) 13,390 (14.8) 14,590 (15.1) 7836 (15.9) 16,599 (15.7) 16,980 (16.2) 15,612 (15.3)
0.5e1, n (%) 14,444 (78.0) 29,883 (77.8) 43,065 (78.8) 58,776 (78.7) 70,635 (78.4) 74,727 (77.6) 37,763 (76.6) 81,445 (77.1) 81,138 (77.5) 79,861 (78.5)
1e1.5, n (%) 159 (0.9) 436 (1.1) 868 (1.6) 1406 (1.9) 1637 (1.8) 2002 (2.1) 1167 (2.4) 2622 (2.5) 2269 (2.2) 2120 (2.1)
1.5e2, n (%) 386 (2.1) 1199 (3.1) 2079 (3.8) 3420 (4.6) 4141 (4.6) 4731 (4.9) 2356 (4.8) 4571 (4.3) 3995 (3.8) 3801 (3.7)
>2, n (%) 60 (0.3) 146 (0.4) 270 (0.5) 237 (0.3) 338 (0.4) 317 (0.3) 138 (0.3) 422 (0.4) 326 (0.3) 415 (0.4)
Daily dosage
Maximum daily dose, n (%) 17,900 (96.7) 36,646 (95.4) 51,402 (94.1) 69,606 (93.2) 84,025 (93.2) 89,317 (92.7) 45,599 (92.6) 98,044 (92.8) 98,136 (93.7) 95,511 (93.8)
>Maximum daily dose, n (%) 605 (3.3) 1781 (4.6) 3217 (5.9) 5063 (6.8) 6116 (6.8) 7050 (7.3) 3661 (7.4) 7615 (7.2) 6572 (6.3) 6398 (6.2)
Table 2
Providers’ characteristics of z-hypnotic prescriptions among the elderly, 2001e2010.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Total prescriptions 18,505 38,427 54,619 74,669 90,141 96,367 49,260 105,659 104,708 101,809
Hospital accreditation level
Medical center, n (%) 6227 (33.6) 11,742 (30.6) 14,263 (26.1) 18,251 (24.4) 20,562 (22.8) 20,824 (21.6) 10,981 (22.3) 22,215 (21.0) 20,977 (20.0) 20,029 (19.7)
Regional hospital, n (%) 5331 (28.8) 111,29 (28.9) 15,196 (27.8) 20,758 (27.8) 23,530 (26.1) 24,392 (25.3) 13,335 (27.1) 28,071 (26.6) 28,286 (27.0) 26,397 (25.9)
District hospital, n (%) 4419 (23.9) 8637 (22.5) 12,688 (23.2) 16,281 (21.8) 18,703 (20.8) 18,958 (19.7) 8780 (17.8) 18,350 (17.4) 17,284 (16.5) 16,061 (15.8)
Clinic, n (%) 2528 (13.7) 6919 (18.0) 12,472 (22.9) 19,379 (26.0) 27,346 (30.3) 32,193 (33.4) 16,164 (32.8) 37,023 (35.0) 38,161 (36.5) 39,322 (38.6)
Physician specialty
Psychiatry, n (%) 2259 (12.2) 4421 (11.5) 5892 (10.8) 7866 (10.5) 10,320 (11.4) 11,090 (11.5) 5461 (11.1) 12,851 (12.2) 14,518 (13.9) 15,996 (15.7)
Neurology, n (%) 2567 (13.9) 5095 (13.3) 6098 (11.2) 7935 (10.6) 9194 (10.2) 9584 (9.9) 5221 (10.6) 10,901 (10.3) 10,432 (10.0) 9833 (9.7)
Cardiology, n (%) 2286 (12.4) 4937 (12.8) 7160 (13.1) 9839 (13.2) 11,575 (12.8) 12,422 (12.9) 6913 (14.0) 14,049 (13.3) 13,485 (12.9) 12,181 (12.0)
Internal medicine, n (%) 6184 (33.4) 12,222 (31.8) 17,066 (31.2) 22,686 (30.4) 26,713 (29.6) 27,682 (28.7) 15,879 (32.2) 32,555 (30.8) 30,944 (29.5) 28791 (28.3)
Family medicine, n (%) 1892 (10.2) 4342 (11.3) 6382 (11.7) 9176 (12.3) 10,714 (11.9) 11,843 (12.3) 9351 (19.0) 21,892 (20.7) 21,856 (20.9) 22103 (21.7)
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a patient received a prescription but could not know the adherence
for taking those medicines. Second, we also could not identify
patients who received z-hypnotics outside the National Health
Insurance system.
Despite these limitations, our empirical ﬁndings revealed a
signiﬁcant nationwide outpatient consumption of z-hypnotics in
Taiwan. To our knowledge, our studywas the ﬁrst one to conduct an
in-depth examination of patients’ and providers’ characteristics
associated with z-hypnotics use among the elderly.
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